Kornimate/medical-research-clean huggingface dataset:
the efficacy of dynamic hand splint treatment in spastic hemiparetic patients

Conditions: Stroke; Brain Injuries

Summary: the purpose of this randomized controlled trial was designed to study the efficacy of dynamic hand splinting on spastic hemiparetic patients due to stroke or traumatic brain injury.

subjects were recruited from both inpatients and outpatients who received rehabilitation programs in the department of physical medicine and rehabilitation at a regional teaching hospital in taiwan. the participants were randomly divided into two groups: the splint group and the control group. the subjects in the splint group received 1-hour task-oriented training with wearing a customized dynamic hand splint, totally 15 times in a duration of one month plus conventional rehabilitation programs. the subjects in the control group received the same treatments but without splint used. evaluations including modified ashworth scale (mas), active range of motion (arom), grip strength, fugl-meyer assessment (fma), motor activity log 30(mal), and f/m ratio were performed at baseline, post-training, and 2 months later after the intervention finished, and the evaluators were blinded to the grouping of the subjects.

Eligibility criteria:
inclusion criteria: * an age of 20 to 85 years * the duration of stroke or brain injury more than 6 months * unilateral hemiparesis with intact sound side limbs function * the brunnstrom's stage of both arm and hand ≥ iii * able to follow instructions, wear a dynamic hand splint and perform therapeutic activities * wrist spasticity with a modified ashworth scale score 1-3 * willing to provide the written informed consent. exclusion criteria: * patients with apraxia * cognitive impairment with a mini-mental state examination (mmse) score \< 25 * any fixed contracture of the affected wrist or fingers * a history of peripheral nerve injury, other severe neuromuscular disease or musculoskeletal deformity change in the affected side upper extremity * a history of alcohol or phenol injection to the affected side upper extremity * botulinum toxin injection to the affected side upper extremity for the treatment of spasticity within 4 months before the study * surgical treatment for spasticity to the affected side upper extremity * active infection * obvious atrophy of muscles in the affected side upper extremity * bilateral upper extremities weakness * any dermatosis or open wounds in the affected upper extremity or an allergy to the splint.

Keywords: spasticity dynamic hand splint stroke traumatic brain injury
remicade® crohn's disease registry across canada (study p02793)

Conditions: Crohn's Disease

Summary: this registry is a multi-center, prospective, observational program that will gather and analyze data on subjects with crohn's disease being treated with remicade® as per approved product monograph in canada. in contrast to a controlled clinical trial, there is no imposed experimental intervention and treatment with remicade® is determined solely by the subject's physicians. thus, the data captured and reported in this registry will reflect a "real world" approach to the treatment of crohn's disease with remicade®.

subjects will be selected for this registry using a non-probability sampling method.

Eligibility criteria:
inclusion criteria: * patient was given the patient information brochure; and, * patient has never been treated with remicade® (patient is naïve to remicade® at the time of registration); and, * patient is a good candidate to receive remicade® as per the product monograph; and, * patient has agreed to complete the patient diary for one week prior to each visit in the registry; and, * patient has signed the approved consent form. exclusion criteria: * per product monograph
home therapy with vpriv in gaucher's disease

Conditions: Gaucher Disease

Summary: the purpose of this study is to proof increasing patient satisfaction and preservation of quality of life in patients with gaucher's disease receiving their enzyme replacement therapy with vpriv (velaglucerase alfa)at their home setting compared to receiving the infusions at the clinic or at doctor's practice.


Eligibility criteria:
inclusion criteria: * male or female patients with a confirmed diagnosis of gaucher disease type 1 * age\> 2 years * patients who have at least 3 infusions (6 weeks) at least 5-year or 5-6 infusions (10-12 weeks) at 2 - to 4-year patients have received vpriv ® and tolerate well * the patient is compliant, the previous vpriv ® infusions were / performed approximately every 2 weeks in the center during office visits * the patient was already before inclusion in this study for a home infusion therapy and has consented to (or their legal representative) * the patient / be lawful. representative has consented in writing to participate in this study. exclusion criteria: • the patient is participating in a clinical trial with a medicinal product
a observational study to evaluate deucravacitinib in patients with moderate plaque psoriasis in china

Conditions: Plaque Psoriasis

Summary: the purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in china.


Eligibility criteria:
inclusion criteria: * participant aged 18 years or older * physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with body surface area ≥ 3% and \< 10% * participant newly initiated deucravacitinib according to the label * provided written informed consent to participate in the study exclusion criteria: * participating in or planning to participate in an interventional clinical trial * concomitant use of other systemic treatments for psoriasis at baseline * prior treatment of deucravacitinib

Keywords: plaque psoriasis
sodium management in acute and chronic heart failure

Conditions: Heart Failure

Summary: the study was aimed to verify the effects of hypertonic saline solution (hss) and a moderate sodium (na) restriction plus high furosemide dose in the short term (hospitalization time) and a moderate na restriction in the long term on readmissions and mortality in patients in iii nyha class.


Eligibility criteria:
inclusion criteria: * decompensated hf due to ischemic or nonischemic cardiomyopathy, * \>18 years of age, * hf according to framingham criteria * nyha functional class iii * ef \<40%, * serum creatinine \<2,5 mg/dl * bun \<60 mg/dl, exclusion criteria: * nyha class \> iii or \< iii, * cerebral vascular disease, * dementia, * cancer, * uncompensated diabetes, * severe hepatic disease * patients requiring pacemaker * previous rct implantation * alcoholic habit

Keywords: heart failure iii nyha class furosemide sodium water restriction decompensated heart failure hypertonic saline solution moderate sodium restriction
context-aware mobile intervention for social recovery in serious mental illness (r33)

Conditions: Schizophenia Disorder; Schizoaffective Disorder

Summary: this randomized clinical trial will test a new technology-supported blended intervention, mobile social interaction therapy by exposure (msite), that targets social engagement in consumers with serious mental illness.

this study evaluates a new technology-supported blended intervention, mobile social interaction therapy by exposure (msite), that targets social behavior, and it also validates several new techniques for measuring social behavior. msite blends brief in-person psychotherapy with a context-triggered mobile smartphone intervention and remote telephone coaching. the investigators will conduct a randomized clinical trial of msite, evaluating whether the intervention leads to clinically significant changes in the frequency of social interactions in comparison to a therapist and device matched condition. the investigators will changes in outcome measures at baseline and weeks 8, 18, and 30. if found to be effective, a scalable intervention that reduces social isolation in serious mental illness would have significant personal, societal, and economic impact.

Eligibility criteria:
inclusion criteria: * voluntary informed consent to participate and capacity to consent; age 18 to 65; * diagnosis of schizophrenia, schizoaffective, bipolar i disorder or major depression with history of psychosis based on a diagnostic interview and available medical record review; * minimum level of social avoidance defined by a score of ≥ 2 on the scale for the assessment of negative symptoms (sans) asociality item; * be willing and able to speak english at ≥ 6th grade reading level (to read intervention workbook). exclusion criteria: * prior cbt in the past 2 years; * greater than moderate disorganization on the panss (p2- disorganization item \>5); * alcohol or substance dependence in past 3 months based on the diagnostic interview; * level of care required interferes with outpatient therapy (e.g., hospitalized; severe medical illness); * unable to adequately see or manually manipulate a phone; * resident of an integrated housing facility that also provides treatment services.

Keywords: schizophrenia serious mental illness msite randomized clinical trial
use of activated recombinant human factor vii to reduce bleeding caused by warfarin treatment

Conditions: Haemostasis; Healthy

Summary: this trial is conducted in the united states of america (usa). the aim of this trial is to evaluate the efficacy of activated recombinant human factor vii to mitigate experimentally-induced bleeding in healthy volunteers treated with warfarin to reach a targeted inr (international normalization ratio).


Eligibility criteria:
inclusion criteria: * inr below or equal to 1.2 exclusion criteria: * the receipt of any investigational drug within 1 month prior to this trial * use of anticoagulation therapy-defined as vitamin k antagonists, platelet antagonists, heparin (or low molecular weight heparin), aspirin or nsaids (non-steroidal anti-inflammatory drug) within 14 days prior to trial * african-american race * weight above 160 kg * supplemental vitamin k use
stereotactic body radiotherapy and radiofrequency ablation for lung tumors near central airways

Conditions: Lung Cancer

Summary: the purpose of this study is to demonstrate that combined stereotactic body radiotherapy and radiofrequency ablation is safe for patients with lung tumors near central airways.


Eligibility criteria:
inclusion criteria: * histologically confirmed primary lung cancer, lung metastasis from another primary, or recurrent tumors in the setting of prior rfa or cryotherapy * tumors \< 2 cm from trachea or zone of proximal bronchial tree (central tumors) * each tumor \< 5 cm in size prior to treatment * medically inoperable patients as determined at the multidisciplinary thoracic tumor board, or medically operable patients who refuse surgery * criterion for medical inoperability include: * overall clinical assessment at the ucla thoracic tumor board * reduced pulmonary function (fev1, dlco, etc) based on one major or two minor criterion as described below: * modified acosog criteria for medical inoperability: * major criteria: fev1% \< 50% or \< 1l and dlco \< 50% * minor criteria: age \> 75, fev1 51-60% predicted, or fev1 1-1.2l, dlco 51%-60% predicted, pulmonary hypertension, poor left ventricular function (ef \ 45 mmhg * age \> 18 years old * kps \> 70 * if a woman is of childbearing potential, a negative urine or serum pregnancy test must be documented. * ability to understand and the willingness to sign a written informed consent exclusion criteria: * prior thoracic radiation near the targets of interest * more than 2 central tumor targets per patient * active infections requiring systemic antibiotics

Keywords: lung tumors central airways
neural therapy effect and bilateral tubal ligation

Conditions: Tubal Obstruction; Dysmenorrhea

Summary: the aim of this study is to evaluate the effect of nebulisation in patients with bilateral tubal ligation in the first postoperative year, the amount of dysmenorrhea, dyspareunia and menstrual bleeding, recurrent vaginitis and cystitis. a retrospective analysis of bilateral tubal ligation with optional modified pomeroy technique in the family planning unit and evaluation of the results of patients who underwent neural therapy during and postoperatively will be evaluated.


Eligibility criteria:
inclusion criteria: * patients who underwent bilateral tubal ligation with modified pomeroy technique, * patients with dysmenore, dyspareunia and menstrual bleeding, exclusion criteria: * postoperative asymptomatic * additional treatments for pain and complaints

Keywords: bilateral tubal ligation postoperative discomforts
change in plaque characteristics with atorvastatin

Conditions: Acute Coronary Syndrome; Atherosclerosis; Dyslipidemia

Summary: to examine effects of intensive lipid lowering therapy with atorvastatin on stabilization of coronary plaque by using optical coherence tomography (oct) in patients with acute coronary syndrome.

patients with acute coronary syndrome (myocardial infarction or unstable angina) who will undergo pci and have at least one atherosclerotic lesion of \>25% stenosis other than culprit lesions of current acs are enrolled. fibrous cap thickness of a target coronary plaque is evaluated by optical coherence tomography.

Eligibility criteria:
inclusion criteria: * patients with acute coronary syndrome (myocardial infarction or unstable angina) who will undergo pci. * plasma ldl cholesterol levels : \>=100mg/dl and ≤160mg/dl * at least one atherosclerotic lesion of \>25% stenosis other than culprit lesions of current acs exclusion criteria: * patients who will undergo coronary bypass surgery. * patients with major complications during treatment of culprit coronary lesions. * patients with an atherosclerotic lesion with \>50% stenosis at a left main trunk.
quality of life in pediatric inflammatory bowel disease

Conditions: Crohn's Disease; Ulcerative Colitis

Summary: measurement of the quality of life (qol) of children and adolescents with inflammatory bowel diseases (ibd) has had little attention, despite the importance of understanding key factors affecting qol, especially for measuring the effects of clinical trials to improve ibd outcomes. the main purpose of this pilot study is to examine the impact of clinical severity and treatment social factors on the quality of life (qol) of a diverse population of children and adolescents with inflammatory bowel disease (ibd). secondary purposes include determining the effects of sociodemographic factors on qol and exploring the concordance of views of parents and children of qol. the study aims are to 1) determine the associations of of clinical characteristics (condition type, activity/severity, and treatment) with specific components of general health-related quality of life and ibd-specific qol; 2) describe the effects of sociodemographic characteristics (ses, age, and gender) on these measures; and 3) compare the views of different observers (parent and child with ibd) of the child's qol. the study will apply both general and condition-specific qol measures among a random sample of 250 children and adolescents with ibd, ages 5-18 years, in six clinical sites. we will obtain measures of qol from both the child and a parent in each case. the study will obtain additional data regarding the subjects' clinical condition (condition type, severity/activity, treatment \[including surgery\], age of onset) and socioeconomic status (household structure and income). main analyses will compare general and specific measures of qol and examine the influence of clinical and sociodemographic variables on qol, through multivariate regression techniques. we will also examine the differences in child and parent assessments of qol. the information from this study will provide a stronger base for future studies of treatment and natural history of ibd. it will help to clarify the life domains that are affected by ibd and will inform interventions to improve qol for children with ibd.


Eligibility criteria:
all children ages 8-17 years in any of six centers for inflammatory bowel disease in children who have already enrolled in the ibd consortium database.

Keywords: pediatric ibd inflammatory bowel
the effects of anesthesia on patients undergoing surgery for repair of a thoracoabdominal aneurysm.

Conditions: Thoracic Aneurysm; Aneurysm Stent; Cardiopulmonary Bypass; Abdominal Aneurysm

Summary: alzheimer's disease represents a growing public health problem in developed countries. although the pathogenesis is not clearly defined, accumulation of extracellular amyloid, neurofibrillary tangles and neuronal loss are the hallmarks of alzheimer's disease. the effect of anesthetic agents on changes in these proteins in humans is not well characterized, but in-vitro evidence suggests that anesthetic agents can accelerate potential pathogenic mechanisms, such as increasing amyloid formation or rates of apoptosis in cultured cells and increasing amyloid levels in mice. human data on the effect of anesthetic agents on amyloid and tau proteins is limited to a small series of 11 patients and showed a significant increase in tau levels after exposure to anesthetics. in this study the investigators propose to measure csf and serum biomarkers in a population of patients with normal csf dynamics, who are undergoing surgery for repair of a thoracoabdominal aneurysm. the investigators will also obtain preliminary data on whether changes in csf levels of these proteins are associated with postoperative delirium or cognitive change.


Eligibility criteria:
inclusion criteria: * age 21-100 years of age * patients presenting for surgical repair of a thoracoabdominal aneurysm * insertion of a csf spinal drain for clinically indicated reason exclusion criteria: * patients with pre-existing delirium * inability to speak and understand english * severe hearing impairment, resulting in inability to converse * pregnancy. pregnancy status will be assessed using a serum pregnancy test during preoperative evaluation as part of the standard of care.

Keywords: thoracoabdominal aneurysm open stent cardiopulmonary abdominal bypass
total knee arthroplasty (tka) cemented versus cementless tibial prosthesis study

Conditions: Osteoarthritis; Post-traumatic Osteoarthritis; Rheumatoid Arthritis

Summary: the primary purpose of tka randomized clinical trial- cemented versus cementless tibial prosthesis study will determine whether there is a significant difference in patient-reported and measured clinical outcomes (e.g. pain, function, length of recovery, and patient satisfaction) between subjects treated with a cementless tibial prosthesis (the cementless group) and those treated with cemented tibial prosthesis (the cement group) over the first two postoperative years. radiographs will be assessed before surgery and at established post-operative intervals to determine if there are any significant differences between patients in the two groups and to assess the influence of component fixation on radiographic stability over time. complication and revision rates will also be assessed for comparison.


Eligibility criteria:
inclusion criteria: * bmi less than \<35 * normal neurological function * primary total knee arthroplasty (pre operative medial knee patient) * patient age ≤ 70 years old exclusion criteria: * revision surgery * history of joint sepsis * recent systemic corticosteroids (\< 2 months prior to procedure) * primary or secondary carcinoma in the last five years * post operative renal transplant * psychosocial disorders limiting rehabilitation * previous intraarticular knee fracture * over 20° valgus or varus deformity * extension loss over 20° * unsuitable for cruciate- substituting arthroplasty * unsuitable for cementless fixation of the tibial component * need for augmentation wedges or bone graft * previous proximal tibial osteotomy
wiser choices in acute myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: patients who are hospitalized because of a heart attack are prescribed a number of medicines to help the heart heal. the investigators will examine different ways in which clinicians share information about those treatment options with patients and the impact that this can have on patients' choices and health.


Eligibility criteria:
inclusion criteria: * between the ages of 18 and 90 * hospitalized at saint marys hospital * a primary diagnosis of ami, * have heart rate, blood pressure, troponin and creatinine measurements, * there is an intention to offer treatment medications * are able and willing to provide informed consent exclusion criteria: * have not had a myocardial infarction * have significant cognitive, visual impairment, * non-english speaker * have a do not intubate/do not resuscitate (dni/dnr) status * will be discharged to a nursing home * ami is not the presumptive diagnosis

Keywords: decision aid heart attack myocardial infarction
tralokinumab in combination with topical corticosteroids in subjects with severe atopic dermatitis - ecztra 7

Conditions: Atopic Dermatitis

Summary: primary objective: to demonstrate that tralokinumab in combination with topical corticosteroids (tcs) is superior to placebo in combination with tcs in treating severe ad in subjects who are not adequately controlled with or have contraindications to oral cyclosporine a (csa). secondary objectives: to evaluate the efficacy of tralokinumab in combination with tcs on severity and extent of ad, itch, and health-related quality of life compared to placebo in combination with tcs. to evaluate the safety of tralokinumab in combination with tcs when treating severe ad in subjects who are not adequately controlled with or have contraindications to oral csa compared to placebo in combination with tcs.


Eligibility criteria:
key inclusion criteria: * age 18 and above * diagnosis of ad as defined by the hanifin and rajka (1980) criteria for ad * history of ad for 1 year or more * subjects with a history within 1 year prior to screening of inadequate response to treatment with topical medications or subjects for whom topical treatments are otherwise medically inadvisable * ad involvement of 10% (or more) body surface area at screening and baseline (visit 3) according to component a of scorad * documented history of either no previous csa exposure and not currently a candidate for csa treatment or previous exposure to csa in which case csa treatment should not be continued or restarted * subjects must have applied a stable dose of emollient twice daily (or more, as needed) for at least 14 days before randomisation key exclusion criteria: * subjects for whom tcss are medically inadvisable in the opinion of the investigator * use of tanning beds or phototherapy (nbuvb, uvb, uva1, puva), within 6 weeks prior to randomisation * treatment with immunomodulatory medications or bleach baths within 4 weeks prior to randomisation * treatment with topical phosphodiesterase-4 (pde-4) inhibitor within 2 weeks prior to randomisation * receipt of any marketed or investigational biologic agent (e.g. cell-depleting agents or dupilumab) within 6 months prior to randomisation or until cell counts return to normal, whichever is longer * history of any active skin infection within 1 week prior to randomisation * history of a clinically significant infection (systemic infection or serious skin infection requiring parenteral treatment) within 4 weeks prior to randomisation * a helminth parasitic infection within 6 months prior to the date informed consent is obtained that has not been treated with, or has failed to respond to, standard of care therapy * tuberculosis requiring treatment within the 12 months prior to screening. evaluation will be according to local guidelines as per local standard of care * history of any known primary immunodeficiency disorder including a positive hiv test at screening, or the subject taking antiretroviral medications